Thomas Hooker, DO
Pulmonary Disease · Hendersonville, NCNPI 1437185204
Payments from drug & device makers
Across 173 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$439
- GSK$421
- Electromed, Inc.$352
- Actelion Pharmaceuticals US, Inc.$275
- AstraZeneca$225
- Regeneron Healthcare Solutions, Inc.$181
- plus $812 from 17 others
What the payments were for
- Food & beverage$2,65698%
- Education$492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 23 | $439 |
| GSK | 31 | $421 |
| Electromed, Inc. | 36 | $352 |
| Actelion Pharmaceuticals US, Inc. | 13 | $275 |
| AstraZeneca | 16 | $225 |
| Regeneron Healthcare Solutions, Inc. | 7 | $181 |
| Philips North America LLC | 8 | $150 |
| Grifols USA, LLC | 6 | $117 |
| Sunovion Pharmaceuticals Inc. | 8 | $104 |
| United Therapeutics Corporation | 3 | $68 |
| Insmed, Inc. | 4 | $63 |
| Mylan Specialty L.p. | 3 | $56 |
| Genentech USA, Inc. | 3 | $41 |
| Merck | 2 | $36 |
| Pulmonx Corporation | 2 | $30 |
| Inogen, Inc. | 1 | $25 |
| Novartis | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Veran Medical Technologies, Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Olympus America Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $13 |
| Fisher & Paykel Healthcare Inc | 1 | $11 |
How this compares
$2,705 in reported general payments places this provider in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 61 | $800,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 216 | $162,345 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 344 | $158,554 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 135 | $81,625 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 130 | $65,304 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $40,543 |
| Spiriva RespimatTiotropium Bromide | 53 | $33,317 |
| Theophylline ErTheophylline Anhydrous | 229 | $23,380 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,294 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $18,527 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $12,862 |
| DuleraMometasone/Formoterol | 19 | $9,136 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $8,500 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $8,341 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $5,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $439 | $915,153249 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $421 | $277,405451 claims |
| AstraZenecaBevespi Aerosphere, Breztri Aerosphere, Symbicort | $225 | $198,376438 claims |
| MerckDulera | $36 | $9,13619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Hendersonville
- Robert CookHendersonville$169K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.